Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others Akribion is pioneering a unique, RNA-guided, nuclease-based technology ...
Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
After hours: January 31 at 5:13:16 PM EST Loading Chart for TENX ...
Sanofi S.A. Part Cert 0.02% €8.03M ...
5 February 2025 The US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100mg/mL for the treatment of diabetic macular edema (DME), said Swiss pharma giant Roche.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback